8-K: Lunai Bioworks Secures $3.13M in Private Placement

Lunai Bioworks Inc. announced a private placement of common stock and warrants to an accredited investor, raising $3.13 million for working capital.

Summary

• Lunai Bioworks Inc. entered into a Securities Purchase Agreement on November 24, 2025, with an accredited investor.
• The company agreed to sell 3,133,333 shares of its common stock at a purchase price of $1.00 per share.
• Additionally, 1,044,444 three-year warrants were issued, which will be executable after sixty (60) days.
• The private placement generated aggregate gross proceeds of $3,133,333.
• The issuance and sale of the shares and warrants were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D.
• No underwriting discounts or commissions were paid in connection with the sale.
• The shares are subject to resale restrictions under Rule 144 and are not registered under the Securities Act or any state securities laws.
• The net proceeds from the sale of the securities are intended for working capital purposes.
• The company will not issue more than 19.9% of its outstanding common stock in this transaction.
• Within ninety (90) days of the completion of the offering, the company will file a registration statement for the resale of the shares and the shares underlying the warrants.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for working capital, which is positive for operations. However, it comes with shareholder dilution and the company noted being not current on some foreign tax returns, which introduces a minor negative aspect. The overall sentiment is moderately positive due to securing funding, but tempered by dilution and minor compliance issues.

Positives

• Successfully raised $3,133,333 in gross proceeds, strengthening the company's financial position.
• The capital infusion is designated for working capital, supporting ongoing operations and strategic initiatives.
• The private placement structure avoided underwriting discounts or commissions, maximizing net proceeds.
• The company plans to file a registration statement for resale within 90 days, potentially providing liquidity for the investor.

Negatives

• The issuance of 3,133,333 new shares and 1,044,444 warrants will result in dilution for existing shareholders.
• The shares are subject to resale restrictions under Rule 144, limiting immediate liquidity for the investor.
• The company is not current in certain foreign income and franchise tax returns due to winding down of certain operations, which could indicate operational challenges or compliance issues in those regions.

Risks

• Actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances.
• Factors that could cause actual results to differ are discussed in the company's Annual Report on Form 10-Q filed November 14, 2025, under 'Risk Factors'.
• The company is not current in certain foreign income and franchise tax returns, reports, and declarations required by some jurisdictions due to winding down of certain operations, which could lead to penalties or legal issues.

Future Outlook

The company intends to use the net proceeds from this private placement for working capital purposes. It also plans to file a registration statement within 90 days of the offering's completion to cover the resale of the newly issued shares and shares underlying the warrants. Forward-looking statements are subject to inherent uncertainties and risks, and actual results may differ materially from current expectations.

Management Comments

• Our decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

Industry Context

This capital raise provides Lunai Bioworks with additional working capital, a common need for biotechnology companies, particularly those in development stages, to fund research, clinical trials, and operational expenses. The use of a private placement with an accredited investor is a frequent strategy for smaller or emerging biotechs to secure funding without the extensive regulatory and marketing efforts of a public offering, though it typically involves dilution and resale restrictions for the investor.

Comparison to Industry Standards

• The $1.00 per share price for common stock in a private placement is a common valuation point for early-stage or smaller biotechnology companies, though specific comparisons would require detailed financial data and pipeline analysis of peers like smaller biopharmaceutical firms listed on Nasdaq.
• The issuance of warrants alongside common stock is a standard incentive in private placements for growth-stage companies, offering additional upside potential to investors in exchange for capital.
• The commitment to file a resale registration statement within 90 days is a typical provision in such private placements, aiming to provide a path to liquidity for the accredited investor, similar to arrangements seen with institutional investors in comparable biotech funding rounds.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new common stock and warrants. However, the capital raise provides funding for company operations, which could support long-term value.
• Investors (Purchaser): The accredited investor gains equity and warrant positions in the company, with a path to liquidity through a future resale registration statement, but faces initial resale restrictions.
• Employees: The capital infusion for working capital helps ensure the company's operational stability, which indirectly benefits employees through continued employment and potential growth.

Next Steps

• The company will use the $3,133,333 in gross proceeds for working capital purposes.
• Within ninety (90) days of the completion of the offering, the company will file a registration statement under the Securities Act covering the resale of the shares and the shares underlying the warrants.
• The company will apply to list or quote all of the Shares on its Trading Market and promptly secure their listing.

Key Dates

Recommendation

The capital raise provides essential working capital, which is a positive for the company's operational stability and ability to pursue its strategic objectives. However, the dilution from the new share issuance and the existence of warrants could put near-term pressure on the stock price. The mention of not being current on some foreign tax returns, while attributed to winding down operations, introduces a minor element of uncertainty. Without more detailed information on the company's pipeline, financial performance, and specific use of funds, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while monitoring future developments and the impact of the new capital.

Keywords

Private Placement, Equity Financing, Common Stock, Warrants, Capital Raise, SEC Filing, Lunai Bioworks, LNAI, Biotechnology, Working Capital